Objective: The clinical importance of neoadjuvant chemotherapy (NAC) followed by definitive surgery was retrospectively investigated in clinical Stage III/IV oral squamous cell carcinoma (OSCC). Methods: Surgery was performed for OSCC in 164 patients, including 72 patients who had received NAC (two cycles of cisplatin and fluorouracil) prior to surgery from January 2004 to December 2014. The clinical characteristics and survival parameters of the groups that received and did not receive NAC were evaluated. The pathological response was classified as Grade 0 (no effect), 1a (very slight effect), 1b (slight effect), 2 (moderate effect) or 3 (marked effect), and its correlation with prognosis was investigated. Results: There were no statistical differences in survival indicators between patients who received NAC and those who did not (overall survival, P = 0.75). The proportion of patients who received NAC in the effective NAC group (Grades 1b, 2, and 3) was 52.8%. After a median follow-up of 35 months, overall survival (P = 0.01), disease-free survival (P = 0.002), locoregional disease-free survival (P = 0.003), and distant disease-free survival (P = 0.01) were significantly better in the effective NAC group than in the less effective NAC group (Grades 0 and 1a). Conclusion: Although NAC had a limited effect on disease prognosis in OSCC, the pathological response to NAC could be an important prognostic indicator for advanced OSCC.
Introduction
The standard therapy for resectable locally advanced oral squamous cell carcinoma (OSCC) is a radical surgery (1) . However, extended surgical resection for OSCC including mandibulectomy may result in significant morbidity and low quality of life after surgery (2, 3) .
Neoadjuvant chemotherapy (NAC) prior to surgery or radiotherapy has been successfully introduced as a therapeutic strategy for advanced head and neck cancers to achieve organ preservation, better locoregional control and improvement in overall survival. Generally, the main purpose of NAC is considered to be organ preservation and improved survival outcome. A study by the Department of Veteran Affairs Laryngeal Study Group demonstrated that significantly higher rates of laryngeal preservation were achieved without diminishing survival outcome in patients with advanced laryngeal cancers who received NAC with cisplatin and 5-fluorouracil (PF) followed by radiation therapy compared with patients who received surgery and postoperative radiation therapy (4) .
The favorable response to NAC in certain cases of OSCC is associated with better survival in several reports (5) (6) (7) . NAC may reduce the risk of distant metastasis, permit mandibular preservation and enable fair disease control in patients with locally advanced OSCC. However, multiple studies of NAC for resectable OSCC have failed to demonstrate significant improvement in locoregional control and overall survival (8) (9) (10) . Thus, further studies are needed to clarify the pathological pattern of tumor shrinkage following NAC and to discover a biomarker for selecting the fair response cases of OSCC. In addition, the treatment protocol for cases with a poor NAC response should be established to improve survival outcome.
The classification of NAC response usually employs the Response Evaluation Criteria in Solid Tumors (RECIST) criteria (11) . The RECIST criteria are based on size alteration of target lesions on imaging examinations. Although RECIST is a useful method for evaluating tumor response, the pathological response to NAC may provide more information on biological activity and quality of tumor shrinkage in OSCC, in which a variable response is seen ranging from almost no effect to a prominent response to NAC.
The aim of this study was to investigate whether the pathological response to NAC in surgically resected samples could be a prognostic indicator in the treatment of OSCC. In such cases, there might be the possibility of organ preservation with fair survival outcome. The ultimate goal of this study is to contribute to the prediction of prognosis and the indications for NAC.
Patients and methods

Participants and study design
This retrospective study was based on a review of clinical records of 164 consecutive patients with OSCC who underwent surgery with curative intent from January 2004 to December 2014 at Aichi Cancer Center. Combined neck dissection and/or reconstructive surgery were performed in addition to primary lesion removal if needed. As a rule, we performed postoperative radiation therapy (60 Gy) with infusion of platinum at the primary site and/or neck within 6 weeks after the operation if there was a positive/close surgical margin (i.e. tumor located <5 mm from the surgical margin) or extracapsular extension. Radiation therapy was adopted instead of chemoradiotherapy as postoperative adjuvant therapy in cases with impaired renal function or those over 75 years old.
The pretreatment evaluation included disease history, physical examination, performance status, serum chemistry profiles, complete blood cell count, chest X-ray, computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography combined with CT (PET-CT). The patient characteristics and clinical features including age, sex, primary site, clinical stage, pathological response to NAC, subsequent treatments, date at which disease progression was noted and oncologic outcomes at the last follow-up examination were recorded. The clinical and pathological tumor staging was performed according to the Union for International Cancer Control (UICC) TNM Classification (seventh edition, 2009). The patient evaluation and decision-making processes were conducted by head and neck surgeons, radiation oncologists and reconstructive surgeons before treatment was initiated. NAC was mainly considered in cases with progressive disease so as to estimate upstaging until surgical intervention or in cases without adequate surgical margin because of tumor spread, for example, primary lesion or cervical lymph node metastasis near the carotid artery or skull base. In addition, patients who receive NAC should be under 70 years old, have ECOG performance status of 0 or 1, and satisfy several hematological and biochemical criteria (serum creatinine concentration ≤1.0 mg/dl, white blood cell count ≥3000/μl, platelet count ≥100 000/μl, hemoglobin concentration ≥10.0 g/dl and aminotransferase and bilirubin values not exceeding twice the upper limit of normal range). The resection volume at surgery was planned considering the tumor extension at the initial clinical assessment. The basic regimen of NAC was 2 cycles of combination of cisplatin (80 mg/m 2 on Day 6) and 5-fluorouracil (800 mg/m 2 on Days 1-5, every 3 weeks). The definitive surgery was performed 3 weeks after NAC. Disease recurrence and progression were evaluated regularly by CT and/or MRI along with physical examinations and endoscopic examination of the head and neck after the above primary treatment protocol was completed.
The study protocol was approved by the Institutional Review Board of Aichi Cancer Center and was conducted in accordance with the principles of the Declaration of Helsinki.
Pathologic evaluation
After surgery, all specimens were carefully evaluated for NAC response. Pathologists in Aichi Cancer Center examined the surgical specimens thoroughly and graded the pathological effects of NAC according to the following criteria of the Japanese Head and Neck Society: Grade 0, no effect; Grade 1(a), very slight effect; Grade 1 (b), slight effect; Grade 2, moderate effect; and Grade 3, marked effect ( Table 1 , Fig. 1 ) (11) . The patients were divided into non-NAC (92 patients) and NAC groups (72 patients), and the NAC group was further sub-classified into less effective NAC group (Grades 0 and 1a; 34 patients) and effective NAC group (Grades 1b, 2 and 3; 38 patients). 
Statistical analysis
Univariate analysis was performed using the chi-squared test for categorical data and the Mann-Whitney U test for continuous variables. The differences within groups were compared using the Cox regression model. In addition to response to NAC, we selected factors known to impact oncologic outcomes, and patient and treatment characteristics, for univariate analysis. A multivariate Cox proportional hazard analysis was used to identify prognostic parameters and treatments associated with locoregional disease-free survival (LDFS), distant disease-free survival (DDFS), disease-free survival (DFS), and overall survival (OS). The significant factors in univariate analysis were added into multivariate analysis. Failures were defined as primary site recurrence, neck lymph node recurrence, and death for LDFS, and as occurrence of distant metastasis and death for DDFS. Survival curves were evaluated by the KaplanMeier method, and survival distributions were compared using the log-rank test. The significant level was set at P = 0.05. All analyses were carried out using JMP ® 9 (SAS Institute Inc., Cary, NC).
Results
Patients' characteristics
Participants comprised 113 men and 51 women with a median age of 63 years (range, 28-90 years). Of the 164 patients, 60 (36.6%) had tumors arising from the lower alveolar ridge. One hundred and eight patients (65.9%) had T4 primary lesions and 73 patients had N2/N3 nodal disease. A total of 108 (65.9%) patients had Stage IV disease. Detailed patient characteristics are shown in Table 2 . The non-NAC group contained a significant number of patients with lower alveolar carcinoma (P = 0.02), while the NAC group had significant number of patients with tongue cancer (P < 0.0001). There were no significant differences in other categories, as shown in Table 2 , between the non-NAC group and NAC group. There were also no significant differences in any clinical category except for lower alveolar carcinoma rate (P < 0.01) between the less effective NAC and effective NAC groups. In total, 98.5% (69/72) of patients underwent surgery within 3 weeks after NAC (median, 21 days). Planned surgery was postponed in one patient due to adverse effects of NAC with Grade 3 febrile neutropenia, and in two patients for other reasons.
Treatment characteristics of the non-NAC and NAC groups
All patients underwent definitive surgery with curative intent. Seventy-two (43.9%) patients received NAC before definitive surgery. Of 164 patients, 112 needed a free flap reconstruction after resection of the primary lesion. Free flap reconstruction was more frequently performed in the NAC group compared with the non-NAC group (P < 0.01), while there was no significant difference in free flap reconstruction between the less effective NAC and effective NAC groups. There were no significant differences in segmental mandibulectomy between the non-NAC and NAC groups and between the less effective NAC and effective NAC groups. Postoperative radiotherapy/chemoradiotherapy (RT/CRT) was more frequently conducted in NAC group than in the non-NAC group, while there was no significant difference in postoperative RT/CRT between the less effective and effective NAC groups. From 2009 to 2014, the completion rate of RT/CRT was 86%. However, there were patients who skipped postoperative radiation therapy because they declined and their general condition was unsatisfactory.
Pathological response to NAC
The pathological response to NAC was examined in all cases that had received NAC ( Table 1 ). The majority (90.3%) of cases showed at least some degree of pathological effect and seven cases had a Grade 0 response. Grades 1b, 2 or 3 responses were observed in 38 (52.8%) of 72 cases that received NAC. A Grade 3 NAC response was observed in six cases, consisting of five with lower alveolar cancer (3 T4 cases, 1 T3 case, and 1 T2 case) and one with mouth floor cancer (T2 case). All patients with Grade 3 NAC responses were alive with no evidence of recurrence during the observation period.
Surgical margin and NAC response
Although all patients had macroscopic tumor-free surgical margins, pathologically positive surgical margins or close margins were observed in 20 and 19 patients, respectively. Positive surgical margin or close margin was observed in 11 cases (15.3%) in the NAC group and in 28 cases (30.4%) in the non-NAC group. There was a statistical difference in the rates of positive or close margin between the groups (P = 0.02). The percentage of cases with a positive or close margin in the effective NAC group was only 7.9% and the difference in percentage compared with the less effective NAC group approached statistical significance (P = 0.07). In addition, there was no positive margin or close margin in cases with Grades 2 and 3 NAC responses.
Extracapsular extension and NAC response
Extracapsular extension (ECE) was observed in 18 (19.6%) of 92 patients in the non-NAC group and 18 (25.0%) of 72 patients in the NAC group. No statistical difference in extracapsular extension was found between the non-NAC and NAC groups or between the less effective NAC and effective NAC groups.
Prognostic impact of pathological response to NAC
The 5-year OS (5-y OS) for all patients was 64.4% after a median follow-up of 35 months. The 5-y OS was 67.4% in the non-NAC group and 63.8% in the NAC group (Fig. 2a) . There was no statistical difference in the 5-y OS between the two groups. However, the 5-y OS was 45.8% in the less effective NAC group and 78.8% in the effective NAC group. The 5-y OS in the effective NAC group was significantly better than that of the less effective NAC group (P = 0.01, Fig. 2b ). Figure 2c shows the OS curves according to pathological response. Grades 1b, 2, and 3 showed much better OS than Grades 0 and 1a.
The 5-y DFS for all patients was 56.1%. The 5-y DFS was 54.3% in the non-NAC group and 58.7% in the NAC group (Fig. 3a) , with no significant difference between the groups. However, the 5-y DFS was 37.3% in the less effective NAC group and 77.9% in the effective NAC group (Fig. 3b) . The 5-y DFS in the effective NAC group was significantly better than those of the less effective NAC (P = 0.002) and non-NAC (P = 0.02) groups.
The 5-y LDFS for all patients was 61.0%, whereas it was 63.0% in the non-NAC group and 60.8% in the NAC group (Fig. 3c) . There was no significant difference in 5-y LDFS between the non-NAC and NAC groups. However, the 5-y LDFS was 43.5% in the less effective NAC group and 71.4% in the effective NAC group. NAC, neoadjuvant chemotherapy; RT/CRT, radiotherapy/chemoradiotherapy. *P < 0.05; **P < 0.01.
The 5-y LDFS in the effective NAC group was significantly better than that in the less effective NAC (P = 0.03, Fig. 3d ). The 5-y DDFS for all patients was 66.2%. The 5-y DDFS was 68.9% in the non-NAC group and 64.2% in the NAC group (Fig. 3e) , and no significant difference was found between the groups. However, the 5-y DDFS was 45.5% in the less effective NAC group and 80.3% in the effective NAC group (Fig. 3f) . The 5-y DDFS of the effective NAC group was significantly better than that of the less effective NAC group (P = 0.01), whereas there was no significant difference in the 5-y DDFS between the effective NAC and non-NAC groups (P = 0.15).
In univariate analysis, positive ECE, positive/close surgical margin, and postoperative RT/CRT were significant risk factors for poor LDFS, DDFS, DFS and OS (Table 3) . Age over 75 was also a significant risk factor for DFS. However, NAC had no significant correlation with LDFS, DDFS, DFS or OS. In multivariate analysis, negative surgical margin could predict a better LDFS, DDFS, DFS and OS compared with a positive surgical margin (Table 3) .
In univariate analysis, the patients in the effective NAC group had better LDFS, DDFS, DFS and OS compared with the less effective NAC group (Table 4) . Postoperative RT/CRT was associated with marginally significant improvement in those survival parameters. In multivariate analysis, the NAC response was also significantly associated with better LDFS, DDFS, DFS, and OS, while postoperative RT/CRT was associated with better DDFS (P = 0.04).
Discussion
The aim of this study was to clarify the effect of NAC on prognosis in surgically treated OSCC. NAC given before surgery or radiotherapy has several theoretical purposes, such as reduction of locoregional disease, reduction in the risk of distant metastases, and improvement of the general condition of the body. These benefits may lead to a better prognosis. Since LDFS, DDFS, DFS and OS in the NAC group were similar to those in the non-NAC group, NAC given for OSCC had no prognostic value. The results were consistent with previous studies on NAC for OSCC (8, 10, (12) (13) (14) . The clinical and pathologic response to NAC is a strong prognostic factor in head and neck cancer (5, 7, 15, 16) . There are significant subsets of patients with head and neck cancer, including OSCC, who respond to NAC (17, 18) . In the present study, the effective NAC group showed better LDFS, DDFS, DFS and OS compared with the less effective NAC group. These results suggest that there is a definite subset of patients who have a better prognosis based on their response to NAC. These patients might be able to skip extensive surgery and postoperative adjuvant therapy. Thus, it is very important to identify the effective cases among OSCC patients.
NAC regimen adding docetaxel to PF (TPF) combination has been reported to be superior to PF in the setting of nonsurgical treatment of locally advanced HNSCC (19, 20) . However, there is still no clear evidence that TPF before surgery improves survival outcome in OSCC compared with PF (13) . The feasibility of using TPF for NAC in surgical treatment remains low in the Japanese context; hence, we investigated the impact of the pathological effect of NAC using the PF regimen in this study.
Patients in the NAC group were different from those in the non-NAC group, with more patients in the NAC group having tongue carcinoma and more undergoing free flap reconstruction and postoperative RT/CRT, though no difference in T and N classifications was observed. These characteristics suggest that the NAC group may include more advanced cases requiring more aggressive therapy compared with the non-NAC group. This selection bias is one of the limitations of this retrospective study. Multivariate analysis of all participants showed that only positive/close margin was a significant prognostic factor in this series. This result suggests that extensive surgery that guarantees a negative margin must be the most important consideration for advanced OSCC treatment. ECE and positive surgical margin are known to be indicators of poor prognosis. For patients with these features, postoperative chemoradiation is recommended (21) (22) (23) (24) (25) (26) . Because the indication for postoperative RT/CRT in this study was ECE or positive/close surgical margin, these three factors became confounding factors for each other.
The effective NAC group had significantly better LDFS, DDFS, DFS and OS in multivariate analysis compared with the less effective NAC group. Figure 2c shows that there is a difference in OS between Grade 0/1a and Grades 1b, 2 and 3. In our series, 38 (52.8%) of 72 patients who underwent 2 cycles of NAC were classified into the effective NAC group and showed a better prognosis than those in the less effective NAC group. Patient characteristics in the effective NAC group were not different from those in the less effective NAC group except for primary tumor site.
In our previous report (11) , a significant correlation of the pathological response to NAC with prognosis was observed in patients with sinonasal squamous cell carcinoma using this pathological grading system that was modified based on classical investigation (27) . Although various NAC protocols were conducted for the treatment of OSCC, the clinical response rates to NAC are Figure 3 . Kaplan-Meier estimation of disease-free survival (DFS), locoregional disease-free survival (LDFS), and distant disease-free survival (DDFS). The logrank test was used to assess survival differences between the groups. (a) The 5-y DFS was 58.7% in the NAC group and 54.3% in the non-NAC group (P = 0.58). (b) The 5-y DFS in the effective NAC group (77.9%) was significantly better than that in the less effective NAC group (37.3%) (P = 0.002). (c) The 5-y LDFS was 63.0% in the non-NAC group and 60.8% in the NAC group (P = 0.93). (d) The 5-y LDFS in the effective NAC group (71.4%) was significantly better than that in the less effective NAC group (43.5%) (P = 0.03). (e) The 5-y DDFS was 68.9% in the non-NAC group and 64.2% in the NAC group (P = 0.86). (f) The 5-y DDFS in the effective NAC group (80.3%) was significantly better than that in the less effective NAC group (45.5%) (P = 0.01).
between 70% and 80% in OSCC (28) (29) (30) . In addition, the clinical complete response rate varied from 24% to 54% (4,31,32). Haddad et al. observed a high rate (89%) of pathological complete response with 3 cycles of TPF (docetaxel, cisplatin, and fluorouracil) as NAC followed by a biopsy of the primary site (33) . Similarly, Wolf et al. reported a complete response rate of 64% that was histologically confirmed by a biopsy in laryngeal cancer (4) . Previous studies reported that the pathological complete response rate to NAC was 25-30% (5,17) . In the present study, we could obtain whole primary and metastatic lesions and investigate the details of pathological response and classify them into five grades. Only six (8.3%) of 72 patients in the NAC group showed a pathological complete response. Here, the number of patients with a complete response is much smaller than those in previous reports. Since the biopsied area of the lesion is limited, it may not provide sufficient tissue sample to diagnose a pathological complete response (5). The RECIST classification is useful for evaluating the response to chemotherapy without the necessity of a biopsy (34) . However, the radiological findings are sometimes inconsistent with the pathological findings at surgery (35) . Further study is needed to find a reliable method for evaluating pathological response to NAC. In a mouse model of head and neck cancer, the feasibility of limited surgery after NAC was investigated, and it was found that pathological and survival outcomes of limited surgery were comparable with those of radical surgery (36) . Evaluating the pathological response to NAC using surgical specimens might enable omission of unnecessary postoperative chemoradiation without diminishing survival outcome.
In a randomized, multicenter trial, Licitra et al. reported the benefit of NAC followed by standard surgery for avoiding not only extensive surgery such as mandibulectomy but also postoperative radiation therapy, without a significant difference in OS in patients with advanced OSCC (14) . Cho et al. demonstrated the benefit of NAC followed by surgery in resectable advanced head and neck cancer (37) . In their series, patients who received NAC and surgery showed a better survival outcome than those who received NAC with radiation. Since the present study was retrospective, we could not evaluate whether less invasive surgery and omission of postoperative adjuvant therapy are possible based on the pathologic response to NAC. However, patients with Grade 3 (complete response to NAC) who did not undergo postoperative adjuvant therapy had no recurrence and no distant metastasis. The pathologic evaluation in the present study is useful for guiding postoperative adjuvant therapy.
One of the aims of NAC is to prevent distant metastasis by reducing tumor burden and diminishing the number of circulating tumor cells. Randomized studies of NAC for laryngeal and hypopharyngeal carcinoma demonstrated an improvement in the control of distant metastasis (4, 31) . In a meta-analysis, NAC significantly reduced the rate of distant metastases in head and neck squamous cell carcinoma including oral cavity cancers (8, 12) . We also reported fair DDFS using multimodality therapy including NAC in sinonasal carcinoma (11) . Although DDFS in the effective NAC group was statistically better than those in the less effective NAC group, there was no significant difference in DDFS between the NAC and non-NAC groups. The result suggests that NAC has a limited effect in preventing DDFS.
The present retrospective study failed to demonstrate improved OS in patients who received NAC. Thus, it is not appropriate for all patients with OSCC to receive NAC. NAC in head and neck cancer has been studied for over three decades; however, its role is still controversial. Although, NAC as a strategy for larynx preservation might be considered as one of the possible options in clinical practice, it has not still demonstrated a meaningful role before definitive surgical intervention for advanced OSCC. In these contexts, the utility of NAC in OSCC should be further investigated in a clinical trial.
A recent randomized controlled trial (RCT) of OSCC with a TPF regimen (13) reported that 8.4% of patients (10 of 119) underwent surgery more than 4 weeks after NAC. Fortunately, our cohort included only three cases with delayed planned surgery (one patient due to adverse effects of NAC and two patients for other reasons). Thus, there is still some risk of delayed definitive surgery or even the possibility of missing the opportunity to undergo definitive surgery due to adverse effects of NAC.
However, detailed pathological evaluation of surgical specimens may be beneficial for identifying a potential chemo-sensitive subgroup of OSCC as well as for predicting cancer prognosis. Thus, further study is needed to clarify the biomarkers of a potential chemo-sensitive subgroup of OSCC, because the subgroup showed fair survival outcome and may have a possibility of organ preservation.
Despite several investigations (6, 38) , the predictors of a fair response to NAC have not been clearly determined. Goenka et al. reported that PET-CT findings after concurrent chemotherapy and radiation could demonstrate regional control in node-positive oropharyngeal cancer (39) . New imaging techniques related to detection of biological activity after NAC should be established to accurately assess residual lesions in OSCC. In a prospective study, p53 gene mutations have been found to be strongly associated with lower response rates to PF based NAC (40) . Moreover, increase tumor expression of beta-Tubulin-II is associated with adverse outcome in HNSCC treated with NAC (41) . Further studies regarding these predictive biomarkers are warranted in order to utilize preoperative drugs in sensitive patients and to avoid drug toxicity in those who are unresponsive. In the future, a large-scale prospective study with sufficient power of selected cohorts might validate the utility of NAC in OSCC.
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